We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Antibodies Against Rabies Detected in Human Dried Blood Spots

By LabMedica International staff writers
Posted on 03 Nov 2020
Print article
Image: Serological test performed at the rabies laboratory. The Bio-Rad Platelia Rabies II ELISA kit is one of the diagnostic assays that are routinely conducted for the determination of antibodies against the rabies virus (Photo courtesy of Korean Animal and Plant Quarantine Agency).
Image: Serological test performed at the rabies laboratory. The Bio-Rad Platelia Rabies II ELISA kit is one of the diagnostic assays that are routinely conducted for the determination of antibodies against the rabies virus (Photo courtesy of Korean Animal and Plant Quarantine Agency).
Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early symptoms can include fever and tingling at the site of exposure. Although preventable by vaccination for more than a century, rabies virus still causes numerous fatalities every year.

Rabies can be difficult to diagnose because, in the early stages, it is easily confused with other diseases or with aggressiveness. The reference method for diagnosing rabies is the fluorescent antibody test (FAT), an immunohistochemistry procedure, which is recommended. The RT-PCR assays proved to be a sensitive and specific tool for routine diagnostic purposes.

Virologists at the Erasmus University Medical Center (Rotterdam, The Netherlands) evaluated the use of human dried blood samples (DBS) for rabies serology and analyzed 99 pre- or post-vaccination serum and DBS samples with a fluorescent antibody virus neutralization test (FAVNt), which is the gold standard to detect protective antibody levels, and the Platelia Rabies II enzyme-linked immunosorbent assay (ELISA) (Bio-Rad, Hercules, CA, USA).

The scientists reported that the DBS-ELISA showed a sensitivity of 86.5% (95% CI 76.6–93.3) and a specificity of 96.0% (95% CI 79.7–99.9) compared to the gold standard serum-FAVNt. The sensitivity increased to 91.6% (95% CI 82.5–96.8) when the DBS-ELISA was compared with serum-ELISA. Moreover, the specificity increased to 100% (95% CI 87.7–100.0). The antibody concentrations measured in DBS eluates and sera correlated significantly when measured with either FAVNt or Platelia-II ELISA.

The authors concluded that both the FAVNt and Platelia-II ELISA demonstrate an acceptable performance on DBS, providing opportunities for rabies serology in remote areas. This technique could drastically ease studies evaluating (novel) rabies vaccination strategies and monitoring persisting immunity in humans at risk, living in rabies endemic regions. The reported high specificities provide confidence that unprotected individuals will rarely be missed. Therefore, the DBS is a promising sampling technique for evaluations of vaccination strategies and monitoring persisting immunity after vaccination in populations at risk for rabies. The study was published on October 13, 2020 in the journal PLOS Neglected Tropical Diseases.



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.